PL321538A1 - Additional protein of a human interleukin-1 receptor - Google Patents

Additional protein of a human interleukin-1 receptor

Info

Publication number
PL321538A1
PL321538A1 PL96321538A PL32153896A PL321538A1 PL 321538 A1 PL321538 A1 PL 321538A1 PL 96321538 A PL96321538 A PL 96321538A PL 32153896 A PL32153896 A PL 32153896A PL 321538 A1 PL321538 A1 PL 321538A1
Authority
PL
Poland
Prior art keywords
receptor
human interleukin
additional protein
protein
additional
Prior art date
Application number
PL96321538A
Other languages
English (en)
Inventor
Richard Anthony Chizzonite
Grace Wong Ju
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL321538A1 publication Critical patent/PL321538A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL96321538A 1995-01-23 1996-01-17 Additional protein of a human interleukin-1 receptor PL321538A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37626895A 1995-01-23 1995-01-23
PCT/EP1996/000181 WO1996023067A1 (en) 1995-01-23 1996-01-17 Human interleukin-1 receptor accessory protein

Publications (1)

Publication Number Publication Date
PL321538A1 true PL321538A1 (en) 1997-12-08

Family

ID=23484321

Family Applications (1)

Application Number Title Priority Date Filing Date
PL96321538A PL321538A1 (en) 1995-01-23 1996-01-17 Additional protein of a human interleukin-1 receptor

Country Status (19)

Country Link
EP (1) EP0808365A1 (no)
JP (1) JPH10512453A (no)
AR (1) AR003919A1 (no)
AU (1) AU4537096A (no)
BR (1) BR9606837A (no)
CA (1) CA2210724A1 (no)
CO (1) CO4480033A1 (no)
CZ (1) CZ208197A3 (no)
EA (1) EA199700265A1 (no)
FI (1) FI973089A0 (no)
HU (1) HUP9702458A2 (no)
IL (1) IL116796A0 (no)
MX (1) MX9705501A (no)
NO (1) NO973404L (no)
PE (1) PE64396A1 (no)
PL (1) PL321538A1 (no)
TR (1) TR199700652T1 (no)
WO (1) WO1996023067A1 (no)
ZA (1) ZA96333B (no)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008969A1 (en) * 1996-08-26 1998-03-05 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
US6974682B1 (en) 1996-08-26 2005-12-13 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
ES2312179T3 (es) 1996-12-06 2009-02-16 Amgen Inc. Terapia combinada que utiliza un inhibidor del il-1 para el tratamiento de enfermedades mediadas por el il-1.
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
EP0979282A1 (en) * 1997-04-30 2000-02-16 F. Hoffmann-La Roche Ag Rat st38.2 chemokine
US6280955B1 (en) * 1997-12-16 2001-08-28 Tularik Inc. Interleukin-1 receptor accessory proteins, nucleic acids and methods
IL136696A0 (en) 1997-12-23 2001-06-14 Immunex Corp Sigirr dna and polypeptides
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
WO2002064630A2 (en) * 2000-10-31 2002-08-22 Immunex Corporation Il-1 receptor accessory protein
GB2375604A (en) * 2001-05-18 2002-11-20 Warner Lambert Co Methods for screening using interleukin soluble trimolecular complex
EP2295081B1 (en) 2001-06-26 2018-10-31 Amgen Inc. Antibodies to OPGL
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US20030049255A1 (en) * 2001-08-07 2003-03-13 Sims John E. Interleukin-1 receptors in the treatment of diseases
KR101317045B1 (ko) 2002-09-06 2013-10-16 암젠 인코포레이티드 치료학적 인체 항-ｉｌ-1ｒ1 모노클로날 항체
RS57852B1 (sr) 2004-04-02 2018-12-31 Swedish Orphan Biovitrum Ab Publ Postupci za smanjenje agregacije il-1ra
EP1751175B1 (en) * 2004-05-05 2012-07-25 VALORISATION-RECHERCHE, Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
US8618054B2 (en) 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
WO2007004060A2 (en) * 2005-05-05 2007-01-11 Valorisation Hsj, Societe En Commandite Cytokine receptor modulators and uses thereof
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
WO2009120905A2 (en) 2008-03-26 2009-10-01 Cellerant Therapeutics, Inc. Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US9403906B2 (en) 2011-01-19 2016-08-02 Cantargia Ab Method of treatment of a solid tumor with interleukin-1 accessory protein antibody
RU2671980C2 (ru) 2011-02-09 2018-11-08 Натера, Инк. Способы неинвазивного пренатального установления плоидности
CA2837651A1 (en) * 2011-06-21 2012-12-27 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
US20180173846A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
US11479812B2 (en) 2015-05-11 2022-10-25 Natera, Inc. Methods and compositions for determining ploidy
JP7114460B2 (ja) * 2015-06-26 2022-08-08 サノフィ・バイオテクノロジー モノクローナル抗ＩＬ－１ＲＡｃＰ抗体
RU2760913C2 (ru) 2016-04-15 2021-12-01 Натера, Инк. Способы выявления рака легкого
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
WO2018022982A1 (en) 2016-07-29 2018-02-01 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
US11773434B2 (en) 2017-06-20 2023-10-03 The Medical College Of Wisconsin, Inc. Assessing transplant complication risk with total cell-free DNA
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
US12024738B2 (en) 2018-04-14 2024-07-02 Natera, Inc. Methods for cancer detection and monitoring
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
WO2021236962A1 (en) 2020-05-20 2021-11-25 The Medical College Of Wisconsin, Inc. Compositions and methods for inhibiting cytokine-release syndrome
CN114835799A (zh) * 2021-05-28 2022-08-02 百奥赛图江苏基因生物技术有限公司 Il1rap基因人源化非人动物的构建方法及应用
AR130550A1 (es) 2022-09-21 2024-12-18 Sanofi Biotechnology Anticuerpo anti-il-1r3 humanizado y métodos de uso

Also Published As

Publication number Publication date
CA2210724A1 (en) 1996-08-01
PE64396A1 (es) 1997-01-28
TR199700652T1 (xx) 1998-02-21
EP0808365A1 (en) 1997-11-26
FI973089A7 (fi) 1997-07-22
MX9705501A (es) 1997-10-31
CO4480033A1 (es) 1997-07-09
IL116796A0 (en) 1996-05-14
FI973089L (fi) 1997-07-22
EA199700265A1 (ru) 1998-04-30
WO1996023067A1 (en) 1996-08-01
FI973089A0 (fi) 1997-07-22
ZA96333B (en) 1996-07-23
NO973404D0 (no) 1997-07-23
HUP9702458A2 (hu) 1998-04-28
AU4537096A (en) 1996-08-14
CZ208197A3 (en) 1997-11-12
NO973404L (no) 1997-07-23
BR9606837A (pt) 1998-05-26
AR003919A1 (es) 1998-09-30
JPH10512453A (ja) 1998-12-02

Similar Documents

Publication Publication Date Title
PL321538A1 (en) Additional protein of a human interleukin-1 receptor
AU2236895A (en) Human g-protein coupled receptors
AU2766395A (en) Human g-protein receptor hgber32
IL116924A (en) Preparation of n-aryl - and n-hetarylhydroxylamines
AU2662695A (en) Human g-protein receptor hpraj70
EP0815133A4 (en) HUMAN STAT4
AU6035398A (en) Human c5a-like receptor
AU2663495A (en) Human g-protein receptor hcegh45
AU4459196A (en) Sustained-release preparation and use
AU8019494A (en) Human endothelin-bombesin receptor
EP0812329A4 (en) HUMAN PROTEIN-G COUPLE RECEPTOR
ZA968873B (en) Isomerisation of equillin
NZ307236A (en) Preparation of streptogramins
IL117786A (en) Preparation of alpha-bisoximes
AU6779798A (en) Novel human cytokine/steroid receptor protein
AU2699695A (en) Human amine receptor
AU1270099A (en) Human progesterone receptor complex p23-like protein
AU4189196A (en) Expression inhibitor against human interleukin-6 receptor
AU2699795A (en) Human g-protein receptor hibef51
HK1005249A (en) Human interleukin-1 receptor accessory protein
GB9511109D0 (en) Receptor proteins
GB9415532D0 (en) Human glutamate receptor protein
GB9403285D0 (en) Human glutamate receptor protein
GB9508618D0 (en) Therapeutic protein
AU2470795A (en) Human neuropeptide receptor